Luminal BC is characterized by the expression of estrogen receptor (ERα) and/or progesterone receptor (PR); HER2+ BC is defined by the overexpression of the human epidermal growth factor (HER2), and triple-negative BC (TNBC) encompasses tumors lacking ERα/PR and HER2 expression [3,4,5]. Here, ERBB2 is linked to breast cancer.